12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
What exactly qualifies as a success in drug R&D may be discussed and disputed in many ways, but nothing lays an argument to rest quite as decisively as the real possibility of blockbuster status.
The data analysts at Clarivate Analytics have just assembled their annual list of all the drugs that are rolling out onto the market this year with a solid shot at breaking the one billion-dollar annual barrier by 2022, and their roster — 12 likely blockbusters which I’ve detailed below — provides some interesting insights into the state of drug R&D today.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
